Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

874 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
Vergote I, Perez Fidalgo A, Valabrega G, Monk BJ, Herzog T, Cibula D, Colombo N, Pothuri B, Sehouli J, Korach J, Barlin J, Papadimitriou CA, van Gorp T, Richardson D, McCarthy M, Antill Y, Mirza MR, Li K, Kalyanapu P, Slomovitz B, Coleman RL. Vergote I, et al. Int J Gynecol Cancer. 2024 Apr 16:ijgc-2024-005412. doi: 10.1136/ijgc-2024-005412. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38627035
Neoadjuvant chemotherapy for ovarian cancer.
Vergote I, van Gorp T, Amant F, Neven P, Berteloot P. Vergote I, et al. Oncology (Williston Park). 2005 Nov;19(12):1615-22; discussion 1623-30. Oncology (Williston Park). 2005. PMID: 16396153 Free article. Review.
Predicting the clinical behavior of ovarian cancer from gene expression profiles.
De Smet F, Pochet NL, Engelen K, Van Gorp T, Van Hummelen P, Marchal K, Amant F, Timmerman D, De Moor BL, Vergote IB. De Smet F, et al. Among authors: vergote ib. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:147-51. doi: 10.1111/j.1525-1438.2006.00321.x. Int J Gynecol Cancer. 2006. PMID: 16515583
The management of borderline tumours of the ovary.
Cadron I, Amant F, Van Gorp T, Neven P, Leunen K, Vergote I. Cadron I, et al. Among authors: vergote i. Curr Opin Oncol. 2006 Sep;18(5):488-93. doi: 10.1097/01.cco.0000239889.98289.ce. Curr Opin Oncol. 2006. PMID: 16894298 Review.
Methodology in plasma proteomic pattern experiments.
Van Gorp T, Vergote IB, Pochet NL, Amant F. Van Gorp T, et al. Among authors: vergote ib. Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1951-2; author reply 1953. doi: 10.1111/j.1525-1438.2006.00721.x. Int J Gynecol Cancer. 2006. PMID: 17009999 No abstract available.
Ovarian cancer.
Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I. Colombo N, et al. Among authors: vergote i. Crit Rev Oncol Hematol. 2006 Nov;60(2):159-79. doi: 10.1016/j.critrevonc.2006.03.004. Epub 2006 Oct 2. Crit Rev Oncol Hematol. 2006. PMID: 17018256 Review.
Management of borderline ovarian neoplasms.
Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Cadron I, et al. Among authors: vergote i. J Clin Oncol. 2007 Jul 10;25(20):2928-37. doi: 10.1200/JCO.2007.10.8076. J Clin Oncol. 2007. PMID: 17617524 Review.
874 results